Trial Overview
NCT ID: NCT06464367 Phase: EARLY_PHASE1 Enrollment Target: 50 Status: Recruiting
In previous clinical trial work, the investigators observed lasting reductions in headache burden after limited dosing of psilocybin. This purpose of this study is to examine potential sources for this observed effect. This study will measure brain resting state functional connectivity (fMRI), central synaptic density (SV2A PET), peripheral markers of inflammation, circadian rhythm (actigraphy), and sleep (sleep EEG) in both migraine and healthy control participants before and one week after the administration of psilocybin or an active control agent.
Why This Matters
[Draft — editorial context needed]
Source
Original Publication
ClinicalTrials.gov
